A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)
Conditions: Chronic Myeloid Leukemia; Chronic Myeloid Leukemia in Remission; BCR-ABL Positive Chronic Myelogenous Leukemia Interventions: Drug: Imatinib; Drug: Nilotinib; Drug: Dasatinib; Drug: Bosutinib Sponsor: National Research Center for Hematology, Russia Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials